RecruitingNot Applicable

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

China20 participantsStarted 2026-01-24

Plain-language summary

Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants voluntarily provided written informed consent for this trial; * Aged 18 to 80 years, inclusive, regardless of gender; * With stable vital signs; * Diagnosis of SBS-IF, confirmed by existing medical/surgical records, receiving parenteral nutrition (PN) due to surgical resection of the small intestine (\<200 cm from the duodenojejunal flexure), and meeting one of the following criteria: * Colon continuity maintained without jejunal/ileal stoma (Type II or III); * Presence of a jejunostomy or ileostomy (Type I); * Expected requirement of PN for more than 4 weeks, with an average PN caloric intake ≥80%; * Ability to comply with the medication dosing and visit schedule; * Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively; * No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection; * No history of drug abuse; * Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants); * No participation in any other drug trials (including the investigational product in this study) within three months prior to enrollment. Exclusion Criteria: * Individuals who do not meet the inclusion criteria or are deemed ineligible by the investigator; * Poor general condition, inability to accurately describe symptoms, presence of severe inf…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Serum Biomarkers of Intestinal Barrier Function

Timeframe: the initiation of enrollment and upon completion of the 28-days treatment period

Trial details

NCT IDNCT07297238

SponsorJinling Hospital, China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05-27

Contact for this trial

Xin Qi, MD

+86 18088680475 qixin199604@126.com

View on ClinicalTrials.gov More Short Bowel Syndrome (SBS) trials